Found: 23
Select item for more details and to access through your institution.
Complete morphologic response to gilteritinib in ALK-rearranged acute myeloid leukemia.
- Published in:
- NPJ Precision Oncology, 2024, v. 8, n. 1, p. 1, doi. 10.1038/s41698-024-00701-y
- By:
- Publication type:
- Article
Differentiation syndrome with lower‐intensity treatments for acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 6, p. 735, doi. 10.1002/ajh.26142
- By:
- Publication type:
- Article
Clinical implications of molecular markers in acute myeloid leukemia.
- Published in:
- European Journal of Haematology, 2019, v. 102, n. 1, p. 20, doi. 10.1111/ejh.13172
- By:
- Publication type:
- Article
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.
- Published in:
- Nature, 2012, v. 485, n. 7397, p. 260, doi. 10.1038/nature11016
- By:
- Publication type:
- Article
AML-091: Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S280, doi. 10.1016/S2152-2650(21)01674-8
- By:
- Publication type:
- Article
Poster: AML-091: Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S210, doi. 10.1016/S2152-2650(21)01314-8
- By:
- Publication type:
- Article
A Phase II Study of Midostaurin and 5-Azacitidine for Untreated Elderly and Unfit Patients With FLT3 Wild-type Acute Myelogenous Leukemia.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Deep learning for diagnosis of acute promyelocytic leukemia via recognition of genomically imprinted morphologic features.
- Published in:
- NPJ Precision Oncology, 2021, v. 5, n. 1, p. 1, doi. 10.1038/s41698-021-00179-y
- By:
- Publication type:
- Article
Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 5, p. 1, doi. 10.1038/s41408-022-00677-7
- By:
- Publication type:
- Article
An Update on FLT3 in Acute Myeloid Leukemia: Pathophysiology and Therapeutic Landscape.
- Published in:
- Current Oncology Reports, 2023, v. 25, n. 4, p. 369, doi. 10.1007/s11912-023-01389-2
- By:
- Publication type:
- Article
Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias.
- Published in:
- British Journal of Haematology, 2012, v. 158, n. 2, p. 198, doi. 10.1111/j.1365-2141.2012.09142.x
- By:
- Publication type:
- Article
Increased body mass index is a risk factor for acute promyelocytic leukemia.
- Published in:
- EJHaem, 2021, v. 2, n. 1, p. 33, doi. 10.1002/jha2.163
- By:
- Publication type:
- Article
The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation–positive relapsed/refractory acute myeloid leukemia.
- Published in:
- Cancer Medicine, 2021, v. 10, n. 3, p. 797, doi. 10.1002/cam4.3652
- By:
- Publication type:
- Article
Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Updates on targeted therapies for acute myeloid leukaemia.
- Published in:
- British Journal of Haematology, 2022, v. 196, n. 2, p. 316, doi. 10.1111/bjh.17746
- By:
- Publication type:
- Article
Advances in targeted therapy for acute myeloid leukaemia.
- Published in:
- British Journal of Haematology, 2018, v. 180, n. 4, p. 484, doi. 10.1111/bjh.15032
- By:
- Publication type:
- Article
FLT3 -ITD Allelic Burden and Acute Promyelocytic Leukemia Risk Stratification.
- Published in:
- Biology (2079-7737), 2021, v. 10, n. 3, p. 243, doi. 10.3390/biology10030243
- By:
- Publication type:
- Article
Arsenic trioxide dose capping to decrease toxicity in the treatment of acute promyelocytic leukemia.
- Published in:
- Journal of Oncology Pharmacy Practice, 2022, v. 28, n. 6, p. 1340, doi. 10.1177/10781552211024727
- By:
- Publication type:
- Article
1q jumping translocation as a biomarker in myeloid malignancy: frequently mutated genes associated with bad prognosis and low survival.
- Published in:
- 2024
- By:
- Publication type:
- Letter
The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond.
- Published in:
- Therapeutic Advances in Hematology, 2014, v. 5, n. 3, p. 65, doi. 10.1177/2040620714532123
- By:
- Publication type:
- Article
Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Case Study: Molecular Profiling in Acute Myeloid Leukemia.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Case Study: Molecular Profiling in Acute Myeloid Leukemia.
- Published in:
- Personalized Medicine in Oncology, 2014, v. 3, n. 2, p. 86
- By:
- Publication type:
- Article